Detalhe da pesquisa
1.
Eomesodermin spatiotemporally orchestrates the early and late stages of NK cell development by targeting KLF2 and T-bet, respectively.
Cell Mol Immunol
; 2024 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38740922
2.
Efficacy and safety of camrelizumab (a PD-1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non-small cell lung cancer.
Oncol Lett
; 24(1): 215, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35720491
3.
Polo-like kinase (PLK) 5, a new member of the PLK family, serves as a biomarker to indicate anabatic tumor burden and poor prognosis for resectable non-small cell lung cancer.
Front Surg
; 9: 964044, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36684318
4.
Full Activation of Kinase Protein Kinase B by Phosphoinositide-Dependent Protein Kinase-1 and Mammalian Target of Rapamycin Complex 2 Is Required for Early Natural Killer Cell Development and Survival.
Front Immunol
; 11: 617404, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33633735
5.
Low serum miR-98 as an unfavorable prognostic biomarker in patients with non-small cell lung cancer.
Cancer Biomark
; 20(3): 283-288, 2017 Sep 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28946561